Huumeongelmaisen hoito

Suosituksen tulostettava versio (pdf) «»1

Tiivistelmä suomeksi «Huumeongelmaisen hoito»1 ja englanniksi «Treatment of Drug-Abusers»2

Potilasversio suomeksi «Huumeongelmaisen hoito»3 ja ruotsiksi «Drogavvänjning»4

Vastuun rajaus

Käypä hoito -suositukset ovat parhaiden asiantuntijoiden laatimia yhteenvetoja yksittäisten sairauksien diagnostiikan ja hoidon vaikuttavuudesta. Ne eivät korvaa lääkärin tai muun terveydenhuollon ammattilaisen omaa arviota yksittäisen potilaan parhaasta mahdollisesta diagnostiikasta ja hoidosta hoitopäätöksiä tehtäessä.

Kirjallisuutta

1. Poikolainen K. Päihteet ja kansanterveys. Kirjassa: Salaspuro M, Kiianmaa K, Seppä K (toim.) Päihdelääketiede. Helsinki: Kustannus Oy Duodecim, 2. uudistettu painos 2003:42-6
2. Suomalainen Lääkäriseura Duodecim. Suomen Päihdelääketieteen yhdistyksen asettama työryhmä. Käypä hoito -suositus Alkoholiongelmaisen hoito. http://www.kaypahoito.fi/
3. Virtanen A. Huumetilanne Suomessa 2004. Huumevuosiraportti EMCDDA:lle Kansallinen huumausaineiden seurantakeskus. Uusin tieto, uusimmat kehityssuuntaukset ja erityisteemat huumeista. Stakes, Tilastoraportteja 1/2005, http://www.stakes.info/files/pdf/Raportit/Reitox2004.pdf
4. Hakkarainen P, Metso L. Huumeiden käytön uusi sukupolvi. Yhteiskuntapolitiikka 2003;68:244-55
5. Partanen P, Hakkarainen P, Holmström P ym. Amfetamiinien ja opiaattien ongelmakäytön yleisyys Suomessa 2002. Yhteiskuntapolitiikka 2004;69:278-86
6. Vuori E, Ojanperä I, Nokua J, Ojansivu RL. Oikeuskemiallisesti todetut myrkytyskuolemat vuosina 2000 ja 2001. Suom Lääkäril 2003;58:3403-7
7. Päihdetilastollinen vuosikirja 2004. Alkoholi ja huumeet. SVT Sosiaaliturva 2004. Helsinki: Stakes, 2004
8. Nuorvala Y, Metso L, Kaukonen O, Haavisto K. Päihde-ehtoinen asiointi sosiaali- ja terveydenhuollossa: vuosien 1995 ja 1999 päihdetapauslaskentojen vertailua. Yhteiskuntapolitiikka 2000;65:246-54
9. Holopainen A, Annala T. Päihdeongelmia terveysnäkökulmasta. Raportti Kettutien A-poliklinikan toiminnasta 2.5.1990-30.04.1993. A-klinikkasäätiön raporttisarja nro 17. Helsinki 1995
10. Ahokas H, Kajesalo K, Holopainen A. Pilvilinnoja vai kunnon rakenteita? Huumeasiakas hoitojärjestelmässä. A-klinikkasäätiön raporttisarja nro 26. Helsinki 1998
11. Baas A, Seppänen-Leiman T. Kadulta korvaushoitoon - Buprenorfiinihoidon kehittämisprojektin (1.1.1998-30.06.2000) loppuraportti. A-klinikkasäätiön raporttisarja nro 38. Helsinki 2002
12. Virtanen A. Suomen Huumausaineseurantakeskuksen kansallinen raportti EMCDDA:lle. Huumausainetilanne Suomessa. Reitox. Stakes 2003
13. Perälä R, Partanen A, Holmström P, Holopainen A. Riskitutkimus selvittää piikkihuumeiden käyttäjien todellisuutta. Tiimi 1/2002
14. Päihdelääketiede. Salaspuro M, Kiianmaa K, Seppä K (toim.) Kustannus Oy Duodecim 2003
15. Päihdepalvelujen laatusuositukset. Sosiaali- ja terveysministeriön oppaita. ISSN 1236-116X; 2002:3. Helsinki 2002, http://pre20031103.stm.fi/suomi/pao/julkaisut/paosisallys165.htm
16. Ponkala VM. Yksilökohtainen palveluohjaus. Työntekijöiden palveluohjausmalli kovien huumausaineiden käyttäjille. Yhteistyötahojen fokusryhmähaastattelut. Helsingin kaupungin sosiaalivirasto. http://www.hel2.fi/sosv/julkaisu/tutkimuksia/2003/2_ponkala.pdf. Tutkimuksia 2003;2:37-48
17. Samyn N. The use of saliva and sweat for the detection of abused drugs in drivers. Väitöskirja 2003, Universiteit Gent, Belgia
18. ROSITA Work Packages amp Deliverables D2 1999, http://www.rosita.org/ (1.12.2000)
19. Grönholm M, Leino A, Saarimies J, Lillsunde P. Huumepikatestien luotettavuuden ja käyttökelpoisuuden arviointi virtsa- ja sylkinäytteistä. Suom Lääkäril 2001;8:871-5
20. Seppälä T, Hoppu K, Leinonen A, Markkanen H, Tanner P, Metso T. Suositus huumetestauksen suorittamisesta. Moodi 2001;25:99-116
21. Lillsunde P, Vanhanen A. Pholcodine in opiate assays – Labquality's drug abuse urine survey 2/1998. Moodi 1999;1:47
22. Huumausainetestien käyttöä selvittäneen työryhmän muistio, STM-työryhmä muistioita 2002:2. Liite 1. Ohjeet hyvän käytännön mukaisesta virtsan huumetestien suorittamisesta, http://pre20031103.stm.fi/suomi/eho/julkaisut/trmuistio2002_2/peruste.pdf
23. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-13
24. Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data. Psychopharmacology 2003;169:115-34
25. Smith F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction 2004;99:425-30
26. Gowing L, Proudfoot H, Henry-Ewards S, Teesson M. Evidence supporting treatment. The effectiveness of interventions for illicit drug use. Australian National Council on Drugs 2001, http://www.ancd.org.au/
27. Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp 2005;312:875-83
28. Vollenweider-Scherpenhuyzen MF, Vollenweider FX. Notfälle bei Drogenmissbrauch. Internist 2000;41:886-98
29. Buchanan JF, Brown CR. 'Designer drugs'. A problem in clinical toxicology. Med Toxicol Adverse Drug Exp 1988;3:1-17
30. Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med 1994;24:68-76
31. Doyon S. The many faces of ecstasy. Curr Opin Pediatr 2001;13:170-6
32. Hegadoren KM, Baker GB, Bourin M. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 1999;23:539-53
33. Liechti ME. "Ecstasy" (MDMA): Pharmakologie, Toxikologie und Behandlung der akuten Intoxikation. Dtsch Med Wochenschr 2003;128:1361-6
34. Saarijärvi S, Lopperi M. Ekstaasin vaikutukset elimistöön. Duodecim 2003;119:1211-5
35. Rochester JA, Kirchner JT. Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology. J Am Board Fam Pract 1999;12:137-42
36. Alho H, Järvenpää E, Seppälä T. Uudet synteettiset huumeet ja päihdetarkoituksessa käytetyt psykotrooppiset aineet. Suom Lääkäril 2001;56:1005-7
37. Laine P. Päihdepotilas terveyskeskuksen päivystyksessä. Duodecim 2002;118:312-6
38. Laine K. Myrkytyksiin liittyvät toksiset oireyhtymät. Duodecim 2000;116:1620-7
39. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:486-7
40. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:486
41. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:514
42. Council on Scientific Affairs. Clinical aspects of amphetamine abuse. JAMA 1978;240:2317-9
43. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:491-2
44. Benowitz NL. Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 1993;72:3-12, erratum in: Pharmacol Toxicol 1993;72:343
45. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L, Goldfrank LR. Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann Emerg Med 1992;21:247-53
46. Karch SB, Stephens B, Ho CH. Relating cocaine blood concentrations to toxicity - an autopsy study of 99 cases. J Forensic Sci 1998;43:41-5
47. Linder MW, Bosse GM, Henderson MT, Midkiff G, Valdes R. Detection of cocaine metabolite in serum and urine: frequency and correlation with medical diagnosis. Clin Chim Acta 2000;295:179-85
48. Hedetoft C, Christensen HR. Amphetamine, ecstasy and cocaine. Clinical aspects of acute poisoning. Danish. Ugeskr Laeger 1999;161:6907-11
49. Williams RG, Kavanagh KM, Teo KK. Pathophysiology and treatment of cocaine toxicity: implications for the heart and cardiovascular system. Can J Cardiol 1996;12:1295-301
50. Brower KJ, Maddahian E, Blow FC, Beresford TP. A comparison of self-reported symptoms and DSM-III-R criteria for cocaine withdrawal. Am J Drug Alcohol Abuse 1988;14:347-56
51. Kajdasz DK, Moore JW, Donepudi H, Cochrane CE, Malcolm RJ. Cardiac and mood-related changes during short-term abstinence from crack cocaine: the identification of possible withdrawal phenomena. Am J Drug Alcohol Abuse 1999;25:629-37
52. Nademanee K, Gorelick DA, Josephson MA ym. Myocardial ischemia during cocaine withdrawal. Ann Intern Med 1989;111:876-80
53. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:492
54. Eiler K, Schaefer MR, Salstrom D, Lowery R. Double-blind comparison of bromocriptine and placebo in cocaine withdrawal. Am J Drug Alcohol Abuse 1995;21:65-79
55. Handelsman L, Rosenblum A, Palij M ym. Bromocriptine for cocaine dependence. A controlled clinical trial. Am J Addict 1997;6:54-64
56. Miller NS, Summers GL, Gold MS. Cocaine dependence: alcohol and other drug dependence and withdrawal characteristics. J Addict Dis 1993;12:25-35
57. Ahtee L. Opioidit ja kannabinoidit. Kirjassa: Salaspuro M, Kiianmaa K, Seppä K (toim.) Päihdelääketiede. Helsinki: Kustannus Oy Duodecim, 2. uudistettu painos 2003:151-60
58. Holopainen A, Fabritius C, Salaspuro M. Opiaattiriippuvuus. Kirjassa: Salaspuro M, Kiianmaa K, Seppä K (toim.) Päihdelääketiede. Helsinki: Kustannus Oy Duodecim, 2. uudistettu painos 2003:468-82
59. Huumeongelma Euroopan Unionissa ja Norjassa. Vuosiraportti 2004, http://annualreport.emcdda.eu.int/download/ar2004-fi.pdf
60. Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 2004;43:329-40
61. Umbricht A, Huestis MA, Cone EJ, Preston KL. Effects of high-dose intravenous buprenorphine in experienced opioid abusers. J Clin Psychopharmacol 2004;24:479-87
62. Ahmadi J, Ahmadi K. Controlled trial of maintenance treatment of intravenous buprenorphine dependence. Ir J Med Sci 2003;172:171-3
63. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005
64. Gueye PN, Megarbane B, Borron SW ym. Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. Addiction 2002;97:1295-304
65. Boyd J, Randell T, Luurila H, Kuisma M. Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 2003;47:1031-3
66. Sporer KA. Buprenorphine: a primer for emergency physicians. Ann Emerg Med 2004;43:580-4
67. Pirnay S, Borron SW, Giudicelli CP, Tourneau J, Baud FJ, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004;99:978-88
68. Linzeris N ym. National clinical guidelines and procedures for the use of buprenorphine in the treatment of heroin dependence. Australia, March 2001:47
69. Alho H. Huumeiden käyttäjä somaattisessa hoidossa. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:488-91
70. Salaspuro M. Opiaattiriippuvuuden näyttöön perustuva hoito ja lääkärin etiikka. Suom Lääkäril 2002;57:5183-9
71. Fudala PJ, Bridge TP, Herbert S ym. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349:949-58
72. Bell J, Byron G, Gibson A, Morris A. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alc Rev 2004;23:311-7
73. Mintzer MZ, Correia CJ, Strain EC. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug Alc Depend 2004;74:205-9
74. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin dependents. Cochrane Review 2005:CD003410
75. Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomised trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur J Clin Invest 2003;33:824-9
76. Hoppu K. Huumeyliannospotilaan hoito. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:485-88
77. Landabaso MA, Iraurgi I, Jimenez-Lerma JM, Calle R, Sanz J, Gutierrez-Fraile M. Ecstasy-induced psychotic disorder: six-month follow-up study. Eur Addict Res 2002;8:133-40
78. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth Edition. Washington, DC, American Psychiatric Association, 1994
79. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 2001;158(Suppl 10):1-52
80. Compton WM 3rd, Cottler LB, Jacobs JL, Ben-Abdallah A, Spitznagel EL. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry 2003;160:890-5
81. Hoffman JA, Caudill BD, Koman JJ 3rd, Luckey JW, Flynn PM, Hubbard RL. Comparative cocaine abuse treatment strategies: enhancing client retention and treatment exposure. J Addict Dis 1994;13:115-28
82. Messina NP, Wish ED, Nemes S. Therapeutic community treatment for substance abusers with antisocial personality disorder. J Subst Abuse Treat 1999;17:121-8
83. Gabbard GO. Psychodynamic Psychiatry in Clinical Practice. 3. painos. Washington DC, American Psychiatric Publishing, 2000
84. Markovitz PJ. Recent trends in the pharmacotherapy of personality disorders. J Personal Disord 2004;18:90-101
85. Kranzler HR, Rosenthal RN. Dual diagnosis: alcoholism and co-morbid psychiatric disorders. Am J Addict 2003;12(Suppl 1):S26-40
86. Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985;142:98-100
87. Hoppu K. Huumeyliannospotilaan tunnistaminen ja huumemyrkytyksen diagnostiikka. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:483-5
88. Leppävuori A. Akuutin psykoosin hoito. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:512
89. de las Cuevas C, Sanz EJ, de la Fuente JA, Padilla J, Berenguer JC. The Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence: SDS validation study. Addiction 2000;95:245-50
90. Topp L, Mattick RP. Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 1997;92:839-45
91. Gossop M, Darke S, Griffiths P ym. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995;90:607-14
92. Petursson H. The benzodiazepine withdrawal syndrome. Addiction 1994;89:1455-9
93. Catzonis SD, Angelopoulos EK, Daskalopoulos EG ym. Convulsive status epilepticus following abrupt high dose benzodiazepine discontinuation. Drug Alcohol Depend 2000;59:95-7
94. Syed NA, Hearing SD, Shaw IS ym. Outbreak of hepatitis A in the injecting drug user and homeless population in Bristol: control by a targeted vaccination programme and possible parenteral transmission. Eur J Gastroenterol Hepatol 2003;15:901-6
95. Lurie P, Gorsky R, Jones TS, Shomphe L. An economical analysis of needle exchance and pharmacy-based programs to increase sterile syringe availability for injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18 (Suppl.1):S126-32
96. Wood E, Kerr T, Spittal PM ym. An external evaluation of peer-run "unsanctioned" syringe exchange program. J Urban Health 2003;80:455-64
97. Hutchinson SJ, Taylor A, Goldberg DJ, Gruel L. Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990-94: implications for control and prevention for blood-borne viruses. Addiction 2000;95:931-40
98. Amundsen EJ, Eskild A, Stigum H, Smith E, Aalen OO. Legal access to needles and syringes / needle exchange programmes versus HIV counselling and testing to prevent transmission of HIV among intravenous drug users: a comparative study of Denmark, Norway and Sweden. Eur J Public Health 2003;13:252-8
99. Strengell P, Vahtola M, Tammela O. Seppä K. Raskaudenaikainen buprenorfiinihoito – riskit ja hyödyt punnittava tarkasti. Duodecim 2005;121:392-9
100. Ralph N, Spigner C. Contraceptive practices among female heroin addicts. Am J Public Health 1986;76:1016-7
101. Mensch B, Kandel DB. Drug use as a risk factor for premarital teen pregnancy and abortion in a national sample of young white women. Demography 1992;29:409-29
102. Vidal-Trecan G, Warszawski J, Coste J ym. Contraceptive practices of non-HIV-seropositive injecting drug users. Eur J Epidemiol 2003;18:863-9
103. Mark I. Medroxyprogesterone acetate as a contraceptive for female drug addicts. Scand J Soc Med 1983;11:75-80
104. Bar-Oz B, Klein J, Karaskov T, Koren G. Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse. Arch Dis Child Fetal Neonatal Ed 2003;88:98-100
105. Lester BM, ElSohly M, Wright LL ym. The Maternal Lifestyle Study: drug use by meconium toxicology and maternal self-report. Pediatrics 2001;107:309-17
106. Ostrea EM Jr, Knapp DK, Tannenbaum L ym. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr 2001;138:344-8
107. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics 1988:101:1079-88
108. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 2001:108:776-89
109. Coutsoudis A, Dabis F, Fawzi W ym. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004;189:12:2154-66
110. MacMahon JR. Perinatal substance abuse: the impact of reporting infants to child protective services. Pediatrics 1997;100:E1
111. Pajulo M, Suchman N, Kalland M, Mayes L. Enhancing the effectiveness of residential treatment for substance abusing pregnant and parenting women: focus on maternal reflective functioning and mother-child relationship. Infant Mental Health J, in press
112. Savonlahti E, Pajulo M, Ahlqvist S ym. Interactive skills of infants with their high-risk mothers. Nord J Psychiatry 2005:59:139-47
113. Burns KA, Chethik L, Burns WJ, Clark R. The early relationship of drug abusing mothers and their infants: an assessment at eight to twelve months of age. J Clin Psychol 1997;53:279-87
114. Kandall SR, Gaines J, Habel L, Davidson G, Jessop D. Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspring. J Pediatr 1993:123:120-6
115. Ornoy A, Segal J, Bar-Hamburger R, Greenbaum C. Developmental outcome of school-age children born to mothers with heroin dependency: importance of environmental factors. Dev Med Child Neurol 2001;43:668-75
116. Lester BM, Boukydis CFZ, Twomey JE. Maternal substance abuse and child outcome. Kirjassa: Handbook of infant mental health. Zeanah CH (toim.) 2. painos. Guilford Press, New York 2000:161-75
117. Singer LT, Minnes S, Short E ym. Cognitive outcomes of preschool children with prenatal cocaine exposure. JAMA 2004:291:2488-56
118. Walsh C, MacMillan HL, Jamieson E. The relationship between parental substance abuse and child maltreatment: findings from the Ontario Health Supplement. Child Abuse Neglect 2003;27:1409-25
119. Ammerman RT, Kolko DJ, Kirisci L, Blackson TC, Dawes MA. Child abuse potential in parents with histories of substance use disorder. Child Abuse Negl 1999;23:1225-38
120. Jaudes PK, Ekwo E, van Voorhis J. Association of drug abuse and child abuse. Child Abuse Negl 1999:9:1065-75
121. Hoppu K. Amfetamiinin yliannos. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:486
122. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:485-6
123. Akuuttihoito-opas. Elonen E, Mäkijärvi M, Voipio-Pulkki LM, Vuoristo M (toim.) Kustannus Oy Duodecim 2005:483-507
124. Alterman AI, Droba M, Antelo RE ym. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend 1992;31:19-29
125. Amato L, Davoli M, Ferri M, Ali R. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Review 2004:CD003409
126. Amato L, Minozzi S, Davoli M ym. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Review 2004, CD005031
127. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatment versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Review 2004:CD004147
128. Amarose AP, Norusis MJ. Cytogenetics of methadone-managed and heroin-addicted pregnant women and their newborn infants. Am J Obstet Gynecol 1976;124:635-40
129. Arlettaz, R, Kashiwagi M, Das-Kundu S, Fauchere JC, Lang A, Bucher HU. Methadone maintenance program in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand 2005;84:145-50
130. Armstrong MA, Gonzales Osejo VG, Lieberman L, Carpenter DM, Pantoja PM, Escobar GJ. Perinatal substance abuse intervention in obstetric clinics decreases adverse neonatal outcomes. J Perinatol 2003;23:3-9
131. Avants SK, Margolin A, Chang P, Kosten TR, Birch S. Acupuncture for the treatment of cocaine addiction. Investigation of a needle puncture control. J Subst Abuse Treat 1995;12:195-205
132. Avants SK, Margolin A, Holford TR, Kosten TR ym. A randomised controlled trial of acupuncture for cocaine dependence. Arch Intern Med 2000;160:2305-12
133. Avants SK, Margolin A, Sindelar JL ym. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of efficacy and cost. Am J Psychiatry 1999;156:27-33
134. Bauer CR, Shankaran S, Bada HS ym. The Maternal Lifestyle Study: drug exposure during pregnancy and short term maternal outcomes. Am J Obstet Gynecol 2002;186:487-95
135. Baker A, Lee NK, Claire M ym. Brief cognitive behavioural interventions for regular amphetamine users: a step in the right direction. Addiction 2005;100:367-78
136. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001;96:683-90
137. Barrowclough C, Haddock G, Tarrier N ym. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001;158:1706-13
138. Barsan WG, Seger D, Danzl DF ym. Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures. Am J Emerg Med 1989;7:155-61
139. Batki SL, Washburn AM, Delucchi K, Jones RT. A controlled trial of fluoxetine in crack cocaine dependence. Drug Alcohol Depend 1996;41:137-42
140. Boer K, Smit BJ, van Huis AM, Hogerzeil HV. Substance use in pregnancy: do we care? Acta Paediatr Suppl 1994;404:65-71
141. Budney AJ, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcomes during treatment for marijuana dependence. J Consult Clin Psychol 2000;68:1051-61
142. Bullock ML, Kiresuk TJ, Pheley AM, Culliton PD, Lenz SK. Auricular acupuncture in the treatment of cocaine abuse. A study of efficacy and dosing. J Subst Abuse Treat 1999;16:31-8
143. Byrne AG, Pierce A. Evaluation of six point of care tests for drugs of abuse in urine. International Association of Forensic Toxicologists Bulletin (TIAFT Bulletin) 2003;33:69-75
144. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addict's risk of fatal heroin overdose. Subst Use Misuse 1996;31:177-96
145. Caplehorn JR, Ross MW. Methadone maintenance and the likelihood of risky needle-sharing. Int J Addict 1995;30:685-98
146. Carreno JE, Alvarez CE, San Narciso GI, Bascaran MT, Diaz M, Bobes J. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addict Biol 2003;8:429-38
147. Carter H, Robinson G, Hanlon C, Hailwood C, Massarotto A. Prevalence of hepatitis B and C infection in methadone clinic population: implications for hepatitis B vaccination. N Z Med J 2001;114:324-6
148. Cejtin HE, Mills A, Swift EL. Effect of methadone on the biophysical profile. J Reprod Med 1996;41:819-22
149. Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 1994;36:115-21
150. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry 1978;35:335-40
151. Comfort M, Kaltenbach KA. Biopsychosocial characteristics and treatment outcomes of pregnant cocaine-dependent women in residential and outpatient substance abuse treatment. J Psychoactive Drugs 1999;31:279-89
152. Copeland J, Swift W, Rees V. Clinical profile of participants in a brief intervention program for cannabis use disorder. J Subst Abuse Treat 2001;20:45-52
153. Crits-Christoph P, Siqueland L, Blaine J ym. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry 1999;56:493-502
154. Crosby RD, Pearson VL, Eller C, Winegarden T, Graves NL. Phenytoin in the treatment of cocaine abuse: a double-blind study. Clin Pharmacol Ther 1996;59:458-68
155. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92:854-8
156. Delaney DB, Larrabee KD, Monga M. Preterm premature rupture of the membranes associated with recent cocaine use. Am J Perinatol 1997;14:285-8
157. D'Ippoliti D, Davoli M, Perucci CA, Pasqualini F, Bargagli AM. Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend 1998;52:167-71
158. De Leon G, Schwartz S. Therapeutic communities: what are the retention rates? Am J Drug Alcohol Abuse 1984;10:267-84
159. de Lima MS, Lima AR, Soares BG ym. A systematic review of pharmacological treatment of cocaine dependence. Management of Substance Sependence. Geneva, WHO 2000
160. DeJong CA, Laheij RJ, Krabbe PF. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomised controlled trial. Addiction 2005;100:206-15
161. Dennis M, Godley SH, Diamond G ym. The Cannabis Youth Ttreatment (CYT) Study: main findings from two randomised trials. J Subst Abuse Treatment 2004;27:197-213
162. Des Jarlais DC, Marmor M, Paone D ym. HIV incidence among injecting users in New York City syringe-exchange programmes. Lancet 1996;348:987-91
163. Drozdick J 3rd, Berghella V, Hill M, Kaltenbach K. Methadone trough levels in pregnancy. Am J Obstet Gynecol 2002;187:1184-8
164. Ebrahim SH, Gfroerer J. Pregnancy-related substance use in the United States during 1996-1998. Obstet Gynecol 2003;101:374-9
165. Edelin KC, Gurganious L, Golar K, Oellerich D, Kyei-Aboagye K, Adel Hamid M. Methadone maintenance in pregnancy: consequences to care and outcome. Obstet Gynecol 1988;71:399-404
166. El-Mohandes A, Herman AA, Nabil El-Khorazaty M, Katta PS, White D, Grylack L. Prenatal care reduces the impact of illicit drug use on perinatal outcomes. J Perinatol 2003;23:354-60
167. Elkashef A, Holmes TH, Bloch DA ym. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction 2005;100(Suppl 1):91-101
168. English DR, Hulse GK, Milne E, Holman CD, Bower CI. Maternal cannabis use and birth weight: a meta-analysis. Addiction 1997;92:1553-60
169. European Pediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. Br J Obstet Gynaecol 2001:108:371-7
170. Evans LE. Use of naloxone in opiate poisoning. Br Med J 1973;2:717
171. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Review 2003, CD002208
172. Felgenhauer N, Zilker T. Intoxikation mit Amphetaminen und Designer-Drogen. Internist 1999;40:617-23
173. Ferguson DM, Horwood LJ, Northstone K; ALSPAC Study team. Maternal use of cannabis and pregnancy outcome. BJOG 2002;109:21-7
174. Fischer G, Johnson RE, Eder H ym. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000;95:239-44
175. Fisher DG, Fenaughty AM, Cagle HH, Wells RS. Needle exchange and injection drug use frequency: a randomized clinical trial. J Acquir Immune Defic Syndr 2003;33:199-205
176. Fridell M. Psychosocial Treatment of Drug Dependence. Kirjassa: Treating Alcohol and Drug Abuse. Berglund M, Thelander S, Jonsson E (toim.) Wiley-VCH 2003:325-413
177. Galloway GP (a), Newmeyer J, Knapp T, Stalcup SA, Smith D. A controlled trial of imipramine for the treatment of methamphetamine dependence. J Subst Abuse Treat 1996;13:493-7
178. Galloway GP (b), Newmeyer J, Knapp T, Stalcup SA, Smith D. Imipramine for the treatment of cocaine and methamphetamine dependence. J Addict Dis 1994;13:201-16
179. Gartner LM, Morton J, Lawrence RA ym. Breastfeeding and the use of human milk. Pediatrics 2005;115:496-506
180. Gawin FH, Morgan C, Kosten TR, Kleber HD. Double-blind evaluation of the effect of acute amantadine on cocaine craving. Psychopharmacology (Berl) 1989;97:402-3
181. George TP, Chawarski MC, Pakes J ym. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry 2000;47:1080-6
182. Gerra G, Marcato A, Caccavari R ym. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995;12:35-41
183. Giannini AJ, Baumgartel P, DiMarzio LR. Bromocriptine therapy in cocaine withdrawal. J Clin Pharmacol 1987;27:267-70
184. Giannini AJ, Billett W. Bromocriptine-desipramine protocol in treatment of cocaine addiction. J Clin Pharmacol 1987;27:549-54
185. Giannini AJ, Folts DJ, Feather JN, Sullivan BS. Bromocriptine and amantadine in cocaine detoxification. Psychiatry Res 1989;29:11-6
186. Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986;15:566-70
187. Gowing L (a), Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Review 2005:CD002022
188. Gowing L (b), Ali R, White J. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Review 2005:CD002021
189. Gowing L, Farrell M, Ali R, White J. Alpha-2-adrenergic agonists for the managing of opioid withdrawal. Cochrane Review 2001;1:CD002024
190. Grabowski J, Rhoades H, Schmitz J ym. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomised clinical trials. Neuropsychpharmacol 2004;29:969-81
191. Grabowski J, Rhoades H, Silverman P ym. Risperidone for the treatment of cocaine dependence: a randomised, double-blind trial. J Clin Psychopharmacol 2000;20:305-10
192. Green M, Silverman I, Suffet F, Taleporos E, Turkel WV. Outcomes of pregnancy for addicts receiving comprehensive care. Am J Drug Alcohol Abuse 1979;6:413-29
193. Green HB, James RA, Gilbert JD, Harpas P, Byard RW. Methadone maintenance programs – a two-edged sword ? Am J For Med Pathol 2000;21:359-61
194. Griffith JD, Rowan-Szal GA, Roark RM, Simpson DD. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend 2002;58:55-66
195. Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse. Psychopharmacology (Berl.) 1997;134:1-37
196. Guenther CD, Fonseca K, Nielsen DM, Wheeler VJ, Pim CP. HIV prevalence remains low among Calgary's needle exchange program participants. Can J Public Health 2000;91:129-32
197. Haddock G, Barrowclough C, Tarrier N ym. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomized controlled trial. Br J Psychiatry 2003;183:418-26
198. Handler A, Kistin N, Davis F, Ferre C. Cocaine use during pregnancy: perinatal outcomes. Am J Epidemiol 1991;133:818-25
199. Harper RG, Solish G, Feingold E, Gersten-Woolf NB, Sokal MM. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. Am J Obstet Gynecol 1977;129:417-24
200. Higgins ST, Budney AJ, Bickel WK ym. Incentives improve outcome in outpatient behavioural treatment of cocaine dependence. Arch Gen Psychiatry 1994;51:568-76
201. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000;162:225-33
202. Hoskins IA, Friedman DM, Frieden FJ, Ordorica SA, Young BK. Relationship between antepartum cocaine abuse, abnormal umbilical artery Doppler velocimetry, and placental abruption. Obstet Gynecol 1991;78;279-82
203. Hulse GK, English DR, Milne E, Holman CD, Bower CI. Maternal cocaine use and low birth weight newborns: a meta-analysis. Addiction 1997;92:1561-70
204. Hulse GK (a), Milne E, English DR, Holman CD. Assessing the relationship between maternal opiate use and neonatal mortality. Addiction 1998;93:1033-42
205. Hulse GK (b), Milne E, English DR, Holman CD. Assessing the relationship between maternal opiate use and antepartum haemorrhage. Addiction 1998;93:1553-8
206. Hulse GK (c), Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997;92:1571-9
207. Hulse GK, O´Neill G. Methadone and the pregnant user: a matter for careful clinical consideration. Aust N Z J Obstet Gynaecol 2001;41:329-32
208. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997;349:1797-800
209. Hämäläinen L. Buprenorfiinista vieroittaminen klonidiinilla. Syventävät opinnot, Oulun yliopisto 2000:1-18
210. Höld KM, de Boer D, Zuidema J, Maes RAA. Saliva as an analytical tool in toxicology. Int J Drug Testing 1996;1:1-29
211. Jain L, Meyer W, Moore C, Tebbett I, Gauthier D, Vidyasagar D. Detection of fetal cocaine exposure by analysis of amniotic fluid. Obstet Gynecol 1993;81:787-90
212. Janiri L, Mannelli P, Persico AM, Serretti A, Tempesta E. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend 1994;36:139-45
213. Jansson LM, Svikis D, Lee J, Paluzzi P, Rutigliano P, Hackerman F. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Treat 1996;13:321-9
214. Jindal RD, Buysse DJ, Thase ME. Maintenance treatment of insomnia: what can we learn from the depression literature? Am J Psychiatry 2004;161:19-24
215. Johansson BA (a). Pharmacotherapy for opioid withdrawal. Kirjassa: Treating Alcohol and Drug Abuse, An Evidence Based Review. Berglund M, Thelander S, Jonsson E (toim.) Wiley-VCH, Wienheim 2003:415-63
216. Johansson BA (b). Pharmacotherapy for opioid dependence. Kirjassa: Treating Alcohol and Drug Abuse, An Evidence Based Review. Berglund M, Thelander S, Jonsson E (toim.) Wiley-VCH, Wienheim 2003:465-531
217. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New Engl J Med 2000;343:1290-7
218. Kakko J, Dybrandt-Svaborg K, Heilig M. Buprenorphine – assisted relapse prevention for heroin dependence: Evidence for superior efficacy in an integrated high-threshold program. Kirjassa: Book of Abstracts. 5th Conference of the European Opiate Addiction Treatment Association. Oslo 2002:47
219. Kampman K, Volpicelli JR, Alterman A ym. Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial. Drug Alcohol Depend 1996;41:25-33
220. Kampman KM, Volpicelli JR, Alterman AI, Cornish J, O'Brien CP. Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am J Psychiatry 2000;157:2052-4
221. Kampman KM, Volpicelli JR, Mulvaney F ym. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001;63:69-78
222. Kashiwagi M, Arlettaz R, Lauper U, Zimmermann R, Hebisch G. Methadone maintenance program in a Swiss perinatal center (I): Management and outcome of 89 pregnancies. Acta Obstet Gynecol Scand 2005;84:140-4
223. Keenan E, Dorman A, O´Connor J. Six year follow-up of forty five pregnant opiate addicts. Ir J Med Sci 1993;162:252-5
224. Killeen TK, Haight B, Brady K ym. The effect of auricular acupuncture on psychophysiological measures of cocaine craving. Issues Ment Health Nurs 2002;23:445-59
225. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Review 2003:CD001333
226. Kosten TR, Morgan CM, Falcione J, Schottenfeld RS. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine and desipramine. Arch Gen Psychiatry 1992;49:894-8
227. Kranzler HR, Bauer LO, Hersch D, Klinghoffer V. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug Alcohol Depend 1995;38:203-11
228. Krook AL, Brörs O, Dahlberg J ym. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction 2002;97:533-42
229. Ksobiech K. A meta-analysis of needle sharing, lending, and borrowing behaviors of needle exhance program attenders. AIDS Educ Prev 2003;15:257-68
230. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction 2004;99:209-14
231. Lamden KH, Kennedy N, Beeching NJ ym. Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England. J Infect 1998;37:260-9
232. Latifa TF, King SM, Roberts EA. Mother-to infant transmission of hepatitis C virus. Hepatology 2001:34:223-9
233. Latukefu RA. Karralika - An evaluation of a therapeutic community for drug users in the Australian Capital territory. National Campaign against Drug abuse, Monograph Series No. 6. Canberra: Commonwealth Australia, 1987
234. Lejeune C, Aubisson S, Simmat-Durand L ym. Syndromes de sevrage des nouveau-nes de meres toxicomanes substituees par la methadone ou la buprenorphine haut dosage. Etude multicentrique prospective de 246 cas. French. Ann Med Interne (Paris) 2001;152:21-7
235. Lerner A, Sigal M, Bacalu A, Shiff R, Bruganski I, Gelkopf M. A naltrexone double blind placebo controlled study in Israel. Isr J Psychiatry Relat Sci 1992;29:36-43
236. Levin FR, Lehman AF. Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. J Clin Psychopharmacol 1991;11:374-8
237. Levine AB, Rebarber A. Methadone maintenance treatment and the nonstress test. J Perinatol 1995;15:229-31
238. Ley A, Jeffery DP, McLaren S, Siegfried N. Treatment programmes for people with both severe mental illness and substance misuse. Cochrane Review 2004:CD001088
239. Lillsunde P, Seppälä T. Huumeseulonta. Kunnallislääkäri 1997;8:27-30
240. Lillsunde P, Korte T. Comprehensive drug screening in urine using solid-phase extraction and combined TLC and GC/MS identification. J Anal Toxicol 1991;15:71-81
241. Ling W, Amassa L, Shotaw S ym. A multi-center randomised trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005;100:1090-100
242. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 2002;97:1395-404
243. Lipton DS, Brewington V, Smith M. Acupuncture for crack-cocaine detoxification: experimental evaluation of efficacy. J Subst Abuse Treat 1994;11:205-15
244. Little BB, Snell LM, Gilstrap LC 3rd. Methamphetamine abuse during pregnancy: outcome and fetal effects. Obstet Gynecol 1988;72:541-4
245. Ludlow JP, Evans SF, Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Austr N Z J Obstet Gynaecol 2004;44:302-6
246. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003;24:363-7
247. Mackenzie AR, Molyneaux PJ, Cadwgan AM, Laing RB, Duoglas JG, Smith CC. Increasing incidence of acute hepatitis B virus infection referrals to the Aberdeen Infection Unit: a matter of concern. Scott Med J 2003;48:73-5
248. Malcolm R, Kajdasz DK, Herron J, Anton RF, Brady KT. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Dru Alcohol Depend 2000;60:161-8
249. Mann AR, Feit MD. An analysis of federal narcotic detoxification policy: implications for rehabilitation. Am J Drug Alcohol Abuse 1982-83;9:289-99
250. Margolin A, Avants SK, Holford TR. Interpreting conflicting findings from clinical trials of auricular acupuncture for cocaine addiction: does treatment context influence outcome? J Altern Complement Med 2002;8:111-21
251. Margolin A, Kleber HD, Avants SK ym. Acupuncture for the treatment of cocaine addiction: a randomized controlled trial. JAMA 2002;287:55-63
252. Marijuana Treatment Project Research Group. Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 2004;72:455-66
253. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998;93:515-32
254. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Review 2003, CD002209
255. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Review 2004, CD002207
256. Mattick RP, Ward J, Hall W. The role of counselling and psychosocial therapy. Kirjassa: Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Ward J, Mattick RP, Hall W (toim.) Amsterdam: Harwood Academic Publishers 1998:265-304
257. Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Review 2005:CD004330
258. McGregor C, Machin A, White JM. In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods. Drug Alcohol Rev 2003;22:175-80
259. McNicholas LF, Martin WR. New and experimental therapeutic roles for naloxone and related opioid antagonists. Drugs 1984;27:81-93
260. Meretniemi K. Huumeenkäyttäjät Suomessa. Tutkimus Helsingin yliopistollisessa keskussairaalan huumevieroitusyksikössä vuosina 1987-1991 hoidetuista potilaista. Moniste
261. Miller JM, Boudreaux MC, Regan FA.A case-control study of cocaine use in pregnancy. Am J Obstet Gynecol 1995;172:180-5
262. Monga M, Weisbrodt NW, Andres RL, Sanborn BM. The acute effect of cocaine exposure on pregnant human myometrial contractile activity. Am J Obstet Gynecol 1993;169:782-5
263. Montoya ID, Levin FR, Fudala PJ, Gorelick DA. Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Depend 1995;38:213-9
264. Mooney EE, Boggess KA, Herbert WN, Layfield LJ. Placental pathology in patients using cocaine: an observational study. Obstet Gynecol 1998;91:925-9
265. Nanovskaya T, Deshmukh S, Brooks M, Ahmed MS. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther 2002;300:26-33
266. National Institute of Health 1997. Consensus Development Statement: Effective medical treatment of heroin addiction. JAMA 1998;280:1936-43
267. Nigam AK, Ray R, Tripathi BM. Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat 1993;10:391-4
268. Norton EC, Zarkin GA, Calingaert B, Bradley CJ. The effect of maternal substance abuse on the cost of neonatal care. Inquiry 1996;33:247-57
269. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-7
270. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004;291:1887-96
271. Nunes EV, McGrath PJ, Quitkin FM ym. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend 1995;39:185-95
272. O'Brien CP. Opiate detoxification: what are the goals? Addiction 2005;100:1035
273. O’Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting: A randomised trial. Ann Intern Med 1997;127:526-30
274. O'Connor PG, Waugh ME, Carroll KM, Rounsaville BJ, Diagkogiannis IA, Schottenfeld RS. Primary care-based ambulatory opioid detoxification: The results of a clinical trial. J Gen Intern Med 1995;10:255-60
275. Osborn DA (a), Cole MJ, Jeffery HE. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Review 2002:CD002059
276. Osborn DA (b), Cole MJ, Jeffery HE. Sedatives for opiate withdrawal in newborn infants. Cochrane Review 2002:CD002053
277. Otto KC, Quinn C, Sung YF. Auricular acupuncture as an adjunctive treatment for cocaine addiction. A pilot study. Am J Addict 1998;7:164-70
278. Pages KP, Ries RK. Use of anticonvulsants in benzodiazepine withdrawal. Am J Addict 1998;7:198-204
279. Paone D, Des Jarlais DC, Gangloff R, Milligen J, Friedman SR. Syringe exchange: HIV prevention, key findings, and future directions. Int J Addict 1995;30:1647-83
280. Parrott AC. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002;71:837-44
281. Petrakis IL, Carroll KM, Nich C ym. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000;95:219-28
282. Quaglio G, Talamini G, Lugoboni F ym. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction 2002;97:985-92
283. Quinlivan JA, Evans SF. The impact of continuing illegal drug use on teenage pregnancy outcomes - a prospective cohort study. BJOG 2002;109:1148-53
284. Raboud JM, Boily MC, Rajeswaran J, O'Shaugnessy MV, Schechter MT. The impact of needle-exhange programs on the spread of HIV among injection drug users: a simulation study. J Urban Health 2003;80:302-20
285. Rawson RA, McCann MJ, Shoptaw SJ ym. Naltrexone for opioid dependence: Evaluation of a manualized psychosocial protocol to enhance treatment response. Drug Alcohol Rev 2001;20:67-78
286. Rayburn WF, Bogenschutz MP. Pharmacotherapy for pregnant women with addictions. Am J Obstet Gynecol 2004;191:1885-97
287. Resti M, Azzari C, Galli L ym. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis 2002:185:567-72
288. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998;88:34-9
289. Richards JR, Derlet RW, Duncan DR. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. J Emerg Med 1998;16:567-73
290. Rosenbach A, Hunot V. The introduction of a methadone prescribing programme to a drug-free treatment service: implications for harm reduction. Addiction 1995;90:815-21
291. Sallee FR, Katikaneni LP, McArthur PD, Ibrahim HM, Nesbitt L, Sethuraman G. Head growth in cocaine-exposed infants: relationship to neonate hair level. J Dev Behav Pediatr 1995;16;77-81
292. SAMSHA guidelines, http://www.health.org/workplace/manguidelines/index.htm (10.10.2000)
293. San L, Pomarol G, Peri JM, Olle JM, Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991;86:983-90
294. SBU (Statens beredning för medicinsk utvärdering): Behandling av alkohol-narkotika problem - en evidensbaserad kunskkapssammanställning. SBU-rapport nr 156/II, SBU, 2001, http://www.sbu.se/
295. Schade A, Marquenie LA, Van Balkom AJ, De Beurs E, Van Dyck R, Van Den Brink W. Do comorbid anxiety disorders in alcohol-dependent patients need specific treatment to prevent relapse? Alcohol Alcohol 2003;38:255-62
296. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment from concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997;54:713-20
297. Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in buprenorphine- versus methadone-maintained patients. J Nerv Ment Dis 1998;186:35-43
298. Schramm W, Smith RH, Graig PA, Kidwell DA. Drugs of abuse in saliva: a review. J Anal Toxicol 1992;16:1-9
299. Schwartz RH, Miller NS. MDMA (ecstasy) and the rave: a review. Pediatrics 1997;100:705-8
300. Sees KL, Delucchi KL, Masson C ym. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283:1303-10
301. Shankaran S, Das A, Bauer CR ym. Association between patterns of maternal substance use and infant birth weight, length and head circumference. Pediatrics 2004;114;e226-34
302. Shearer J, Wodak A, Mattick RP ym. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001;96:1289-96
303. Shearer J, Wodak A, Van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003;98:1137-41
304. Shiono PH, Klebanoff MA, Nugent RP ym. The impact of cocaine and marijuana use on low birth weight and preterm birth: a multicenter study. Am J Obstet Gynecol 1995;172:19-27
305. Smith MT, Perlis ML, Park A ym. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 2002;159:5-11
306. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 1999;14:287-303
307. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Review 2003:CD003022
308. Srisurapanont M (a), Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine withdrawal. Cochrane Review 2003:CD003021
309. Srisurapanont M (b), Kittiratanapaiboon P, Jarusuraisin N. Treatment for amphetamine psychosis. Cochrane Review 2003:CD003026
310. Stephens RS, Curtin L, Simpson EE, Roffman RA. Testing the abstinence violation effect construct with marijuana cessation. Addict Behav 1994;19:23-32
311. Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol 2000;68:898-908
312. Stein MD, Solomon DA, Herman DS ym. Pharmacotherapy plus psychotherapy for treatment of depression in active injection drug users. Arch Gen Psychiatry 2004;61:152-9, erratum in Arch Gen Psychiatry 2005;62;224
313. Stimmel B, Adamsons K. Narcotic dependency in pregnancy. Methadone maintenance compared to use of street drugs. JAMA 1976;235:1121-4
314. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomised trial. JAMA 1999;281:1000-5
315. Sweeney PJ, Schwartz RM, Mattis NG, Vohr B. The effect of integrating substance abuse treatment with prenatal care on birth outcome. J Perinatol 2000;4:219-24
316. Tennant FS Jr, Sagherian AA. Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch Intern Med 1987;147:109-12
317. Torfs CP, Velie EM, Oechsli FW, Bateson TF, Curry CJ. A population-based study of gastroschisis: demographic, pregnancy, and lifestyle risk factors. Teratology 1994;50:44-53
318. Tutton CS, Crayton JW. Current pharmacotherapies for cocaine abuse: a review. J Addict Dis 1993;12:109-27
319. Uralets VP, Gillette PA, Medina FC. GC/MS comprehensive benzodiazepine screen statistical distribution of different drugs in routine testing in in the United States. The International Association of Forensic Toxicologists, 38th International Meeting TIAFT 2000, Helsinki, Abstract book 2000:136
320. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. Br Med J 1998;317:433-7
321. van den Bosch LM, Verheul R, Schippers GM, van den Brink W. Dialectical Behavior Therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addict Behav 2002;27:911-23
322. Vanhanen AR, Lillsunde P. Kokemuksia huumaus- ja lääkeainemääritysten laadunarvioinnissa 1998-2002. Moodi 2002;26:62-6
323. Verster A, Buning E. Info for policymakers on the effectiveness of substituion treatment for opiate dependence. Euromethwork 2003, http://www.euromethwork.org/
324. Vlahov D, Junge B, Brookmeyer R ym. Reduction in high-risk drug use behaviors among participants in the Baltimore needle exchange program. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:400-6
325. Vuori E, Henry JA, Ojanperä I ym. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 2003;98:365-8
326. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003;70(Suppl 2):S13-S27
327. Wang X, Dow-Edwards D, Anderson V, Minkoff H, Hurd YL. In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry 2004;56:909-15
328. Wang X, Dow-Edwards D, Keller E, Hurd YL. Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience 2003;118:681-94
329. Ward J, Mattick RP, Hall W. The use of methadone during maintenance treatment: Pharmacology, dosage and treatment outcome. Kirjassa: Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Ward J, Mattick RP, Hall W (toim.) Amsterdam: Harwood Academic Publishers 1998:205-38
330. Weddington WW Jr, Brown BS, Haertzen CA ym. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am J Drug Alcohol Abuse 1991;17:137-52
331. Weinbroum A, Halpern P, Geller E. The use of flumazenil in the management of acute drug poisoning - a review. Int Care Med 1991;17(Suppl 1):S32-8
332. Weinbroum AA, Flaishon R, Sorkine P, Szold O, Rudick V. A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. Drug Saf 1997;17:181-96
333. Weinmann S, Kunstmann W, Rheinberger P. Metadone substitution – a scientific review in the context of out-patient therapy in Germany. Z Arztl Fortbild Qualitatssich 2004;98:673-82
334. Weisdorf T, Parran TV Jr, Graham A, Snyder C. Comparison of pregnancy-specific interventions to a traditional treatment program for cocaine-addicted pregnant women. J Subst Abuse Treat 1999;16:39-45
335. Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Treatment of benzodiazepine dependence in methadone maintenance treatment patients: a comparison of two therapeutic modalities and the role of psychiatric comorbidity. Austr N Z J Psych 2003;37:458-63
336. White R. Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. Addiction 2000;95:229-38
337. Wouldes TA, Roberts AB, Pryor JE, Bagnall C, Gunn TR. The effect of methadone treatment on the quantity and quality of human fetal movement. Neurotoxicol Teratol 2004;26:23-34
338. EuropASI (European Addiction Severity Index). Päihderiippuvuuden vaikeusasteen arviointi. Ohjekirja. Eurooppalainen versio 1998